Cargando…

Molecular characteristics and tumorigenicity of ascites‐derived tumor cells: mitochondrial oxidative phosphorylation as a novel therapy target in ovarian cancer

Ovarian cancer disseminates primarily intraperitoneally. Detached tumor cell aggregates (spheroids) from the primary tumor are regarded as ‘metastatic units’ that exhibit a low sensitivity to classical chemotherapy, probably due to their unique molecular characteristics. We have analyzed the cellula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Yi, Labitzky, Vera, Legler, Karen, Qi, Minyue, Schumacher, Udo, Schmalfeldt, Barbara, Stürken, Christine, Oliveira‐Ferrer, Leticia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637562/ https://www.ncbi.nlm.nih.gov/pubmed/34060699 http://dx.doi.org/10.1002/1878-0261.13028

Ejemplares similares

Ovarian Cancer-Cell Pericellular Hyaluronan Deposition Negatively Impacts Prognosis of Ovarian Cancer Patients
por: Oliveira-Ferrer, Leticia, et al.
Publicado: (2022)

Insights into the Steps of Breast Cancer–Brain Metastases Development: Tumor Cell Interactions with the Blood–Brain Barrier
por: Hamester, Fabienne, et al.
Publicado: (2022)

The role of the desmosomal protein desmocollin 2 in tumour progression in triple negative breast cancer patients
por: Reimer, Francesca, et al.
Publicado: (2023)

Prognostic Impact of CEACAM1 in Node-Negative Ovarian Cancer Patients
por: Oliveira-Ferrer, Leticia, et al.
Publicado: (2018)

Ang-2 is a potential molecular marker for lymphatic metastasis and better response to bevacizumab therapy in ovarian cancer
por: Volk, Annabelle, et al.
Publicado: (2023)

Key Role of Hyaluronan Metabolism for the Development of Brain Metastases in Triple-Negative Breast Cancer
por: Hamester, Fabienne, et al.
Publicado: (2022)

VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients
por: Kuerti, Sascha, et al.
Publicado: (2017)

VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients
por: Ding, Yi, et al.
Publicado: (2022)

Prognostic relevance of the Golgi mannosidase MAN1A1 in ovarian cancer: impact of N-glycosylation on tumour cell aggregation
por: Hamester, Fabienne, et al.
Publicado: (2019)

Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells in vitro
por: Brauneck, Franziska, et al.
Publicado: (2023)

Impact of AKT1 on cell invasion and radiosensitivity in a triple negative breast cancer cell line developing brain metastasis
por: Kempska, Joanna, et al.
Publicado: (2023)

E- and P-Selectins Are Essential for Repopulation of Chronic Myelogenous and Chronic Eosinophilic Leukemias in a Scid Mouse Xenograft Model
por: Wicklein, Daniel, et al.
Publicado: (2013)

Reduced mannosidase MAN1A1 expression leads to aberrant N-glycosylation and impaired survival in breast cancer
por: Legler, Karen, et al.
Publicado: (2018)

CXCR3 mediates ascites-directed tumor cell migration and predicts poor outcome in ovarian cancer patients
por: Windmüller, C, et al.
Publicado: (2017)

The initial engraftment of tumor cells is critical for the future growth pattern: a mathematical study based on simulations and animal experiments
por: Hoffmann, Bertin, et al.
Publicado: (2020)

Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer
por: Weimer, Pauline, et al.
Publicado: (2022)

BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer
por: Elazezy, Maha, et al.
Publicado: (2021)

Immune Tumor Microenvironment in Ovarian Cancer Ascites
por: Almeida-Nunes, Diana Luísa, et al.
Publicado: (2022)

Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer
por: Prieske, Katharina, et al.
Publicado: (2017)

CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients
por: Heinze, Karolin, et al.
Publicado: (2021)

Ascitic complement system in ovarian cancer
por: Bjørge, L, et al.
Publicado: (2005)

The bright side of ascites in ovarian cancer
por: Cohen, Marie, et al.
Publicado: (2014)

Ascites Volumes and the Ovarian Cancer Microenvironment
por: Penet, Marie-France, et al.
Publicado: (2018)

Enhanced tumorigenicity by mitochondrial DNA mild mutations
por: Cruz-Bermúdez, Alberto, et al.
Publicado: (2015)

Pro-Tumorigenic Phosphorylation of p120 Catenin in Renal and Breast Cancer
por: Kourtidis, Antonis, et al.
Publicado: (2015)

Disaggregation and invasion of ovarian carcinoma ascites spheroids
por: Burleson, Kathryn M, et al.
Publicado: (2006)

Deciphering the ovarian cancer ascites fluid peptidome
por: Bery, Anand, et al.
Publicado: (2014)

Chlamydia Peritonitis and Ascites Mimicking Ovarian Cancer
por: Gojayev, Anar, et al.
Publicado: (2016)

Spontaneous bacterial peritonitis complicating ovarian hyperstimulation syndrome-related ascites
por: Taniguchi, Leandro Utino, et al.
Publicado: (2011)

Oncolytic adenovirus inhibits malignant ascites of advanced ovarian cancer by reprogramming the ascitic immune microenvironment
por: Shi, Gang, et al.
Publicado: (2021)

Metabolomic and Mitochondrial Fingerprinting of the Epithelial-to-Mesenchymal Transition (EMT) in Non-Tumorigenic and Tumorigenic Human Breast Cells
por: Cuyàs, Elisabet, et al.
Publicado: (2022)

ARHGAP10, downregulated in ovarian cancer, suppresses tumorigenicity of ovarian cancer cells
por: Luo, N, et al.
Publicado: (2016)

OXIDATIVE PHOSPHORYLATION AND ULTRASTRUCTURAL TRANSFORMATION IN MITOCHONDRIA IN THE INTACT ASCITES TUMOR CELL
por: Hackenbrock, Charles R., et al.
Publicado: (1971)

Correction: Enhanced tumorigenicity by mitochondrial DNA mild mutations
por: Cruz-Bermúdez, Alberto, et al.
Publicado: (2020)

PIM kinases inhibit AMPK activation and promote tumorigenicity by phosphorylating LKB1
por: Mung, Kwan Long, et al.
Publicado: (2021)

Mirk kinase inhibition targets ovarian cancer ascites
por: Deng, Xiaobing, et al.
Publicado: (2014)

The untapped potential of ascites in ovarian cancer research and treatment
por: Ford, Caroline Elizabeth, et al.
Publicado: (2020)

TRRAP stimulates the tumorigenic potential of ovarian cancer stem cells
por: Kang, Kyung Taek, et al.
Publicado: (2018)

Asbestos Exposure and Ovarian Cancer – a Gynaecological Occupational Disease. Background, Mandatory Notification, Practical Approach
por: Nowak, Dennis, et al.
Publicado: (2021)

Mitochondrial genetics – new model uncovering roles in tumorigenicity and metastasis
por: Beadnell, Thomas C., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_v949ffmb7tnbnl7h27ub78k700